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Abstract
Background: Internationally, overdose is the primary cause of death among people injecting drugs. However, since
2001, heroin-related overdose deaths in the United States (US) have risen sixfold, paralleled by a rise in the death
rate attributed to synthetic opioids, particularly the fentanyls. This paper considers the adaptations some US heroin
injectors are making to protect themselves from these risks.
Methods: Between 2015 and 2016, a team of ethnographers collected data through semi-structured interviews and
observation captured in field notes and video recording of heroin preparation/consumption. Ninety-one current
heroin injectors were interviewed (Baltimore, n = 22; Chicago, n = 24; Massachusetts and New Hampshire, n = 36;
San Francisco, n = 9). Experience injecting heroin ranged from < 1–47 years. Eight participants, who were exclusively
heroin snorters, were also interviewed. Data were analyzed thematically.
Results: Across the study sites, multiple methods of sampling “heroin” were identified, sometimes used in combination,
ranging from non-injecting routes (snorting, smoking or tasting a small amount prior to injection) to injecting a partial
dose and waiting. Partial injection took different forms: a “slow shot” where the user injected a portion of the solution in
the syringe, keeping the needle in the injection site, and continuing or withdrawing the syringe or a “tester shot” where
the solution was divided into separate injections. Other techniques included getting feedback from others using heroin of
the same batch or observing those with higher tolerance injecting heroin from the same batch before judging how
much to inject themselves. Although a minority of those interviewed described using these drug sampling techniques,
there is clearly receptivity among some users to protecting themselves by using a variety of methods.
Conclusions: The use of drug sampling as a means of preventing an overdose from injection drug use reduces the
quantity absorbed at any one time allowing users to monitor drug strength and titrate their dose accordingly. Given the
highly unpredictable potency of the drugs currently being sold as heroin in the US, universal precautions should be
adopted more widely. Further research is needed into facilitators and barriers to the uptake of these drug
sampling methods.
Keywords: Overdose, Heroin, Fentanyl, Test shot, Tester shot, Injection, Insufflation, Inhalation, Harm reduction, United
States
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Background
Heroin can be taken into the human body in a wide var-
iety of ways, including snorting or sniffing powder or
heroin solution (intranasal use), inhalation of the heated
vapors (“chasing”), orally and as anal suppositories
(“plugging”). Injecting, whether intravenous, subcutane-
ous or intramuscular, is the method of administration
carrying the highest risk for multiple types of infections,
overdoses and their complications [1–15]. However, des-
pite these risks, injection appeals to users because it is
the most efficient, cost-effective method of use, and
intravenous injection in particular has the most intense
onset of effect (“rush”). These can be important consid-
erations when users face rising tolerance to heroin’s
effects [16, 17].
Heroin “source form”—its chemical characteristics
based on country of origin—also influences its mode of
use [18, 19]. Bioavailability, or the measure of a drug dose
that achieves circulation in the bloodstream, in turn re-
flects the mode of use. The three main source forms of
heroin in the US—Colombian-sourced powdered heroin
and both Mexican-sourced black tar heroin and powdered
heroin—are all hydrochloride salts in contrast with the
Afghanistan-sourced base heroin, aka “smoking heroin,”
found in Europe [20]. The hydrochloride (HCL) form has
relatively low bioavailability when smoked compared with
base heroin [21]. Heroin HCL may be potentiated when
smoked by the addition of caffeine [22], but research indi-
cates no significant culture of heroin smoking in the US
[23, 24] likely due to available source forms. Use outside
of controlled conditions [25] as well as poor chasing tech-
nique [26] may also negatively affect the bioavailability of
smoked heroin.
Another non-injection option to chasing/smoking is
intranasal use. Intranasal heroin administration has been
found to be an effective drug delivery route. It has been
theorized that the lower price of US heroin in the early
1990s rather than its higher purity—as well as fears of
contracting HIV—may have led to increased usage of in-
tranasal administration [27]. US data on hospitalizations
in the 1990s suggests an increase in heroin inhalation
and smoking, primarily in the northeast during this
period [28].
For many decades, overdose has been the primary
cause of deaths among people injecting drugs [6, 9, 29–
32], but since 2001, heroin-related overdose deaths have
risen sixfold in the United States [33]. Heroin-related
overdose intensified after 2010, with overdose mortality
rates tripling between 2010 and 2014 from 1.0 to 3.4 per
100,000 [34]. The increase in heroin-related deaths has
been paralleled by a rise in the death rate attributed to
synthetic opioids other than methadone. The age-
adjusted rate of overdose deaths attributed to synthetic
opioids other than methadone, which includes fentanyl
and its analogs, doubled between 2015 and 2016, rising
to 6.2 per 100,000 [35]. Evidence from the US Drug
Enforcement Agency indicates this increase is being
primarily driven by illicitly manufactured fentanyl rather
than diverted pharmaceutical fentanyl [36, 37]. While
some have focused on the potency of fentanyl [38, 39] in
increasing the risk for overdose, others have highlighted
the risk of vicissitudes in the purity of fentanyl and its
analogs in combination with heroin [40, 41].
In the face of overdose-related morbidity and mortal-
ity, numerous public health interventions have tried to
address the risks of overdose over the last 20 years.
These strategies include overdose education and peer
naloxone distribution [42–44]. Promoting what has been
termed “reverse transition” from injecting to a non-
injecting route of administration constitutes another ap-
proach to reducing overdose risk [45].
One study of UK-based “chasers” and injectors found
that while preferred administration routes were likely to
persist for years and multiple route transitions were un-
common, 16% of their sample had reverse transitioned
[46]. Another study of reverse transitions among heroin
and cocaine users in New York City found that transi-
tion from injection to non-injection use appeared to be
a relatively stable, long-term behavior change [47].
Among other transitions, several harm reduction organi-
zations in the UK advocated for switching to rectal ad-
ministration ("plugging"), the so-called “up your bum”
campaign, but it is unclear how widespread this practice
actually is [48, 49].
Given the low rate of “chasing” among US heroin users,
one practice some injectors have adopted to reduce the
risk of overdose is the use of “tester shots” or “test shots.”
This entails injecting a small quantity of a drug sample in
order to assess its potency qualitatively before deciding
whether to inject the remainder of the dose [50–52]. A
tester shot requires practitioners to perform two injec-
tions, a factor that may act as a barrier to the widespread
adoption of this behavior, as venous access can become
challenging for long-term injectors and higher injection
frequency increases the risk of injection-related complica-
tions including viral transmission [2, 53].
Circumventing the multiple injection problem of the
tester shot, “slow shots” allow the injector to insert the
needle, release the tourniquet, and very slowly inject
while assessing the embodied effect with the needle still
in the vein [54]. A further refinement of this is the
“graduated” or “controlled” shot where the needle re-
mains in the vein, but the dose is divided into three with
a pause for assessment of its effects between each third
[55]. The term “tester shot” is used in this paper to en-
compass all forms of partial dose injection, while “drug
sampling” refers to any method of administration involv-
ing a partial dose.
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There is a dearth of qualitative research on behavioral
adaptions that current heroin injectors are making with
respect to the ongoing fentanyl adulteration crisis in the
US. In this paper, we present findings from ethnographic
fieldwork trips in 2015 and 2016 to Baltimore, Maryland;
Worcester, Lowell, and Lawrence, Massachusetts; Nashua,
New Hampshire; San Francisco, California; and Chicago,
Illinois on embodied methods of gauging opioid strength
that injection drug users in these areas are taking to pre-
vent overdose. With the exception of California, where
solid black tar heroin dominates, all these states have pow-
der sourced from Mexico or Colombia and are suffering
rising heroin- and fentanyl-related deaths.
In 2016, Baltimore lost 454 people to heroin-related
overdoses, up from 260 the previous year, and 419
people to fentanyl-related overdoses, up from 120 in
2015 [56, 57]. The figures available for Massachusetts do
not distinguish between heroin and prescription opioids.
In 2016, among the 1374 individuals whose deaths were
opioid-related (including heroin) and a toxicology screen
was also available, 1031 of them (75%) had a positive
screen result for fentanyl, an increase from 754 (57%) in
2015, although this may depend on the frequency of
toxicological screening [58, 59]. Drug overdose deaths in
New Hampshire increased by 1629% between 2010 and
2015, largely as a result of fentanyl. Hillsborough
County, the location of Nashua, where 43.6% of the fen-
tanyl deaths occurred, was most affected by these over-
dose deaths. The rate of death caused by fentanyl,
heroin, and other opioids rose sharply between 2015 and
2016 [60]. In Chicago in 2016, there were 487 overdose
deaths involving heroin and 420 involving fentanyl, both
rising from the previous year [61]. In San Francisco in
2016, 41 deaths were attributed to heroin overdose and
22 attributed to fentanyl, doubling from the previous
year [62, 63]. Data for 2017 are not available for all sites,
but Baltimore showed a small decline in heroin-related
deaths (from 334 in January to September 2016 to 305
in the same period of 2017) but a much larger increase
in fentanyl-related deaths (from 276 January to Septem-
ber 2016 to 427 in the same period in 2017) [64]. Massa-
chusetts experienced a modest decline in overall opioid
deaths in 2017 but an increase in the proportion screen-
ing positive for fentanyl (to 83%) [65].
Methods
The “Heroin in Transition” (HIT) study is conducting
“hotspot” research where ethnographers are dispatched
to locations around the country upon receiving reports
of unusual or dangerous heroin or high levels of over-
dose [40]. HIT’s approach is adapted from “rapid assess-
ment,” a short-term multidisciplinary research model
aimed at gaining an insider perspective of social, eco-
nomic or health problems and their possible solutions
[66]. Originally developed in the 1970s, rapid assessment
has enabled researchers to gain knowledge about emer-
ging health problems in a short time period and has
been used effectively in investigating health concerns re-
lated to drug use [67–69].
HIT uses highly focused ethnography to investigate
new and evolving heroin forms and users’ responses,
their methods and contexts of use [17]. The paucity of
data regarding the risks associated with novel heroin
forms of unknown purity and modes of use, along with
contamination of the heroin supply with fentanyl [41]
and the urgent need for knowledge acquisition to de-
velop interventions, makes rapid ethnography highly ap-
propriate to this time sensitive problem.
Unlike most rapid assessment, the HIT model is
chiefly qualitative, with quantitative questions explored
by the Heroin in Transition study outside the rapid as-
sessment to inform the overall picture. Our research
model aims to represent “from below” the experiences
and perceptions of users in the current opioid epidemic.
These data are placed alongside observations by the
ethnographers based on their own experience of observ-
ing heroin and its use in other locations. Data are not
formally triangulated, but we hope that a composite pic-
ture emerges from the multiple perspectives of users
and ethnographers. Further, rapid ethnography allows us
to generate hypotheses to be tested by quantitative re-
search methods. Between 2015 and 2016, the ethno-
graphic team visited Baltimore, Maryland (November
2015 and March 2016); San Francisco, California (Febru-
ary 2016); the Massachusetts cities of Lawrence, Lowell,
Worcester and Nashua, New Hampshire (June 2016);
and Chicago, Illinois (September 2016).
Recruitment and data collection
Following information about fentanyl-laced and fentanyl-
substituted heroin in Baltimore, New Hampshire and
Massachusetts and high levels of overdose in Chicago,
contact was made with harm reduction service providers
in these locations. In San Francisco, the ethnographic
team used personal contacts to arrange interviews with
users and also carried out recruitment on the street. The
study protocol was also approved by the University of
California, San Francisco Institutional Review Board. The
data and its collection are protected by a US Federal
Certificate of Confidentiality issued by the National Insti-
tutes of Health/National Institute on Drug Abuse.
Data were collected through semi-structured interviews,
ethnographic observation captured in collaborative field
notes and video recording of heroin preparation and
consumption. With its observation in the field and long
established “ground-up” approach to data collection, eth-
nography is a method well suited for examining the experi-
ences and phenomena of everyday life—and has been used
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widely in research among drug users [3, 70]. Rapid ethnog-
raphy uses a more directed and condensed approach than
traditional ethnography, collecting data with a particular set
of questions in mind.
To be eligible for the study, participants had to be at
least 18 years of age and self-reported current injectors
whose primary drug was heroin. Exclusion criteria covered
individuals who were intoxicated or otherwise unable to
give informed consent or answer questions reliably. Re-
searchers approached users attending needle and syringe
program sites, explained the study to them, and obtained
their consent. Some snowball sampling was also con-
ducted [71]. Only verbal consent is sought to avoid the
collection of participants’ full names or signatures. Pam-
phlets approved by UCSF IRB explaining the study and re-
spondents’ rights were also provided. Interviews are
conducted in as private a setting as possible. Before the
interview begins, the research participants are reminded
that they are free to decline to answer any question or to
leave or stop talking to the researcher at any time. The
team carries mobile phones for emergencies. Respondents
received a small cash sum in compensation for their inter-
view (approximately 0.5–1 h), aiming to balance respect
for participants’ time while not acting as an inducement
for users to participate [72]. All participants were inter-
viewed once while some provided neighborhood tours or
permitted the ethnographers to observe and film heroin
injections.
The semi-structured interviews were carried out by
the ethnographers (JO, EW, FMC and MH), project
director (SM), and PI (DC) immediately upon
recruitment at the needle and syringe program
locations, in rental cars, cafés, users’ homes or drug-
using locations. An interview guide provided a general
structure to the conversation, including questions on
the respondents’ life course of drug use, a typical day
in their life involving drug acquisition and use,
perceived changes in the heroin supply, knowledge of
fentanyl, preferences for heroin vs. fentanyl, methods
of use, perceived physiological effects and experiences
of overdose.
After our initial visit to Baltimore indicated some
tester shot usage among the population, focused
questioning on drug sampling was incorporated into the
interview guide for subsequent sites. All interviews were
audio-recorded and transcribed in their totality and
verified (by JO) against the audio recording. Field notes
were drafted collaboratively each research day and
finalized after the trips. The PI (DC) is a physician and
can address participants’ medical concerns or questions
or that arise during the flow of this research. As data is
analyzed, findings are fed back to local service providers
to assist in the development of tailored harm reduction
responses.
Sample characteristics
This was a non-random convenience sample. Across all
sites, 91 current heroin injectors were interviewed (Balti-
more, n = 22; Chicago, n = 24; Massachusetts and New
Hampshire, n = 36; San Francisco, n = 9), of whom 62
were male and 29 were female. The experience injecting
heroin ranged from less than a year to 47 years. Eight
participants, who were dedicated heroin snorters, were
also interviewed. Names have been changed to protect
confidentiality.
Analysis
Transcripts were read in their entirety, and text relating to
tester shots/snorting and other harm reduction methods
were extracted by JO and discussed by JO, DC, and SM,
who then clarified categories of activity, motivation, prov-
enance and other themes arising from the data. Observa-
tions from the field notes and video recording were also
incorporated in the analysis. The analysis gave priority to
the ways in which people experience heroin but also in-
cluded the reflections of the ethnographers observing the
drugs and their administration.
Some degree of subjectivity and contextual influence are
present in all data interpretation, but the ethnographers
maintained an awareness of this, discussing and examin-
ing their own positionality and preexisting ideas at mul-
tiple points during the research process. Data analysis was
conducted by three multidisciplinary researchers with
diverse life experiences, disciplinary backgrounds, age, and
mixed genders. Where discrepancies in the interpretation
of the findings arose, these were discussed until agreement
was reached.
Results
Motives
The unpredictability of heroin potency is a long-
established problem of its illicit supply, particularly for
injectors whose dose is delivered in a single “bolus,” put-
ting them at increased risk of overdose relative to those
who insufflate (toot, snort or sniff ) or smoke heroin.
Users become aware of these risks in a number of ways,
including personally experiencing or witnessing over-
doses or losing friends or partners. The research study’s
first encounter with drug sampling was with a young
man in San Francisco who, after experiencing an over-
dose, had started smoking the strong black tar heroin
known locally as “point dope” before judging how much
to inject:
I’ll smoke it just to see how I feel from taking a
couple of hits and then I’ll only do a point [0.1g] or if
I’m really spooked, like, even less, just try it out. […]
Yeah, you know what’s funny though, I didn’t always
do that until I had OD’ed and then I was like “Oh
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fuck! Now I’m playing with my life here.” (Riley, in his
20s, using for 7 years)
Like Riley, some interviewees mentioned adopting
drug sampling as a result of experiencing overdose first-
hand, but others did so after observing others. Liz from
Lawrence, MA, a woman in her 20s who had been
injecting for 1 year and had never personally overdosed,
explained that she had adapted her behavior with
fentanyl-laced heroin, “Because you learn from every-
body else being stupid”:
[…]when I get stuff I don’t know what it is, I do a little
bit before I do something that I feel. Like I want to kind
of scale out how much I want to do. Because I don’t
want to die. But these people are just doing a gram shot
and just… my friend just died two days ago.
While some referred to these methods as their regular
practice, others sampled in particular circumstances
such as after periods of abstinence or when the heroin
or its source were unfamiliar. In Chicago, David, who
was in his 30s and had been using for 7 years, generally
relied upon a regular dealer to regulate the quality and
strength of his heroin, as well as keeping his doses small,
but he snorted heroin prior to injecting when buying
from an unfamiliar source:
Q: Do you ever taste a new bag?
A: No, because I’ve been going through the same guy
and it’s just always consistent. His is always, you
know, straightforward. You know what you’re going
to get. So I trust it. But if I were to go to somebody
else that I hadn’t gone to before I would definitely
taste it, snort a little bit, or you know if I were to
shoot it, I would shoot a small amount. Because you
can always shoot more, you can never shoot less.
Drug sampling methods
Users described a wide variety of methods for drug sam-
pling, sometimes creatively combining them together,
from using non-injecting routes of administration such
as snorting, smoking or tasting a small amount prior to
injection to injecting a partial dose and waiting. Partial
injection could take different forms: either a “slow shot”
where the user injected a portion of the solution in the
syringe, keeping the needle in the injection site, and then
either continuing or withdrawing the syringe or a “tester
shot” where the solution was divided between two or
more separate injections. Other techniques included get-
ting feedback from other users who were using heroin of
the same batch or observing other users with higher
tolerance injecting heroin from the same batch before
judging how much to inject themselves.
Drug sampling by snorting and tasting
In Chicago, where the powder heroin can be snorted ra-
ther than smoked, several injectors described snorting
their heroin before injecting. Ray, in his 50s and using for
25 years, explained that this not only gave an indication of
its strength but also a taste at the back of the throat which,
he believed, was indicative of its ingredients:
A: […] I’m not the only one that do this. There’s a lot
of my buddies that do heroin too, will toot [snort] it
first before we even start cooking it up to see what’s it
about. […]See, when you toot dope it’s supposed to go
down your nose and it’s supposed to go down smooth
without no burn or none of that… Now, once you get
that drain, it’s the taste. It tastes like dope. Because
see, some dope that tastes like aspirin ain’t dope…. So
you get familiar with the taste of dope too once you
do it, once you had done it so long with me…. So
once you get all that in perspective, […] the taste, the
smoothness going down, the drain, you’ll start feeling
a nice, warm sensation. So now I know it’s straight
[heroin] so it’s time for me to party now.
Tester shot
Several of our research participants indicated that they
had begun injecting a smaller amount of heroin to assess
qualitatively its embodied effects before injecting a larger
dose. Johnny in Chicago, in his 20s and using for 6 years,
was among those who endorsed this method:
A: […] I’m very cautious on my heroin intake. I like to
know how much I’m doing. And if anything, I always
do a little bit less and sometimes I get pissed off
because I don’t get high from the little shot.
Q: So you take care of yourself, testing a little bit.
A: I always test the waters before. You don’t just jump
in with heroin.
Glen, in his 20s, using for approximately 1 year in Bal-
timore, described his method of tester shot:
Q: How long are you waiting to judge how strong it
is?
A: I’d say anywhere from 5 to 15 minutes.
Q: 5 to 15 minutes. You’re a patient guy. I imagine a
lot of other people aren’t so patient.
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A; Well, it’s… pays off in the end, I guess.
Half-dose slow shot
Some of those interviewed had managed to avoid over-
dose entirely, perhaps as a result of using drug sampling
methods. Larry, a Baltimore man in his 60s who had sur-
vived over 40 years of heroin use without overdosing,
explained how he injected half his shot of heroin, waited
a short time, and then decided whether to inject the rest.
If he decided to inject the rest of the shot after waiting,
he registered to check whether he was still accessing the
vein first. We asked him about how he managed the de-
cision not to use the whole shot:
Q: So what happens if you’re feeling like that half shot
is really good, do you have enough self-control to take
the rest of it out and not do it?
A: Yeah, I can. And I also like to have it where I can
put the rest of it in me, because I feel as though my
intake can allow me to take the rest of that there.
Combined tester and slow shots
James, a Baltimore man in his 50s who had been inject-
ing for half his life and never overdosed, had recently ex-
perienced a number of friends dying from overdoses.
His method involved loading the syringe with half the
dose and then further dividing the half doses for a slow
shot:
A: […] I don’t, what they call, slam it and put the
whole thing in me. I do it little by little just to see
what the effects is and stuff.
Q: So do you like have one syringe and you use a little
bit of it or do you like have several syringes?
A: No, just one syringe and one syringe I put what
we say 80 on the height. So once I cook it up and
do what I’m going to do with it, and most of the
time I’ll speedball, you know, cocaine and heroin.
And I will take 40 of it and I’ll take the other 40
and put it to the side and then when I hit myself
I’ll just put 20 in it just to see, you know, what the
effects is …
Combined user report and slow shot
Janice, also a long-term user in Baltimore, in her 50s,
who had also never overdosed, used a combination of
approaches to regulate her intake. This involved getting
an oral report from a friend, gauging how much to dilute
the heroin depending on her friend’s reaction, and then
taking a half-dose slow shot, keeping the needle in place
before deciding whether to use more.
Q: … Since you don’t know whether it’s going to be
weak or strong how do you manage that?
A: What I do is I get a reading from someone else
because I know myself.
Q: A reading?
A: Meaning they tell me how it is for them. And that
determines how much water I’ll put on mine. Like my
girlfriend might say, 'Girl, that dope is good as a
motherfucker.' I might put 40 on it and I’ll put a 60.
[…]
Q: You dilute it if the strength is good?
A: Yes.
Q: All right. Then how do you inject that 60? […]
A: 30.
Q: You’ll do 30?
A: I’ll do 30, wait for it to hit me and see if I can
handle it or do I need to come out.
Q: How long you waiting for?
A: As soon as it hit me. Which usually takes I’d say 20
seconds.
Q: 20 seconds, okay. And then you just decide to pull
out or –?
A: Or go ahead with it.
Mixed heroin-tolerance partners
Relying on friends’ experiences of a single batch was also
something we observed in Baltimore. Glen and Scott are
running buddies sharing resources including heroin [3].
Glen had only started injecting in the last year after a
brief period snorting heroin following his transition from
opioid pills. Scott, in his 40s, had a higher opiate toler-
ance after using heroin for many years and acted as
“taster.” In this case, Glen heated a speedball in a single
cooker, dividing the solution equally between two syrin-
ges. After Glen had injected Scott in his neck, Scott re-
ported on its strength and advised Glen to go ahead and
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inject his own dose. Although Glen’s tolerance was
lower, they shared equal doses, perhaps an equity
demanded by their friendship, but took care to keep
each other safe.
Users’ reflections on drug sampling
However, there are limits to the drug sampling strategies
just described, especially in the age of fentanyl. Harry, a
user in his 40s from Lowell, MA, using for 20 years, ex-
plained that even with a tester shot, he had almost over-
dosed from heroin he later believed to contain fentanyl:
I almost overdosed, I almost died. I almost went out.
And I didn’t do much, it was kind of like a tester shot
and it was really powerful. I just thought it was really
good dope, you know? I didn’t know it was fentanyl
until it started getting around that the fentanyl was
floating around…
Whether users developed these methods themselves,
learnt them from peers, publicity campaigns or harm
reduction workers was often unclear. However, an
awareness of the irreversibility of injection was a recur-
ring theme.
I’m taking my time because if I’m gonna mix it with
65 [units of water], I’m gonna put 10 or 15 in me to
see the quality of what I’m putting in me, because you
can always put more in, but can’t take it out. I’m a
firm believer in that.—Doug, Baltimore, in his 40s,
using for 32 years
I’ll do a little bit at a time just to make sure I’m not –
that I’m cool. And then you can always give yourself
more but you can’t take back.—Joanie, Chicago, in her
30s, using for 14 years
Q: Do you ever do a tester shot or do you use the
whole thing in one shot?
A: It depends on the drug, sometimes I don’t do it all
at once. You have to respect dope; if you know it’s
strong, you have to use it carefully.—Gonzalo,
Nashua, NH, in his 50s, using for 20 years
Q: And you were saying a bit about how you avoid
ODing yourself?
A: Oh yeah, because I don’t, you know, push the
whole thing in me at one time, because like I said,
there is no pulling it back […] once you push it in
you, ain’t no trying to pull it back […]—James,
Baltimore
The presence of overdose as an imminent danger was
especially pervasive among users in Baltimore and Mas-
sachusetts, many of whom had lost friends, relatives or
acquaintances. Although a minority of those interviewed
described using these drug sampling techniques, there is
clearly receptivity among some users to protecting
themselves by using a variety of methods.
Discussion
Our ethnographic research shows that in the five states
visited for this study, some people using heroin have in-
corporated tester shots and other drug sampling strat-
egies into their injection practices. These included a
wide range of approaches, sometimes in combination, in
which people used their own or others’ embodied expe-
riences to judge the strength of the drug qualitatively
before deciding on their dose. While these methods do
not guarantee safety from an overdose, particularly in
the cases of some of the more powerful fentanyls, it
would be valuable to test epidemiologically whether
those using drug sampling methods report experiencing
fewer overdoses.
Peer advocacy for tester shots and drug sampling may
be the most effective means of expanding the use of these
methods. A number of research studies conducted in the
US and internationally have demonstrated the connection
between social norms, peer adoption, self-efficacy and per-
ceived acceptability in the successful adoption of harm re-
duction strategies [73–77]. Other research has
demonstrated how social norms within drug-using groups
influence the perception of risks and acceptable practices
[78]. The promotion of drug sampling methods between
peers as a form of harm reduction therefore needs to be
done in a way that reflects the structural risks of the re-
gional drug economy and an awareness of local norms
among users. For instance, to advise users to sample their
heroin by smoking before injecting might be suitable
where a base form of the drug, such as Afghanistan-
sourced heroin, is dominant, but in the case of US powder
heroin, much of the drug would be lost before absorption
and snorting prior to injection would be a better option.
Alternatively, where heroin prices are high and/or avail-
ability is low, tester shots may be more appealing than
snorting. Aside from these market considerations, further
research into facilitators and barriers to the uptake of
drug sampling is needed. Barriers suggested to date are a
loss of intensity from spreading the dose over time and
“wasting” heroin through less effective delivery methods
such as snorting [26, 79].
Psychologically informed approaches may also shed
some light on how best to encourage the use of drug
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sampling. One survey of the self-efficacy of harm reduc-
tion practices, including tester shots, found that adher-
ence to all harm reduction strategies surveyed was
markedly lower when respondents were asked to im-
agine being in withdrawal [80]. A later study identified
being in a hurry to use (24%) and purchasing drugs from
a known dealer (20%) as the most significant barriers to
the adoption of tester shots [81]. Health beliefs about
perceived susceptibility to and severity of overdose may
influence the adoption of overdose-related harm reduc-
tion methods such as tester shots [82]. Many of those
we spoke with reported the recent deaths of friends,
family and acquaintances [17, 41], as well as experien-
cing their own overdoses. We do not know whether de-
cisions to use drug sampling strategies are shaped more
by psychological or situational factors.
In order for tester shots and other drug sampling
strategies to be effective at preventing overdose, people
who inject heroin must be willing to use them consist-
ently, since risk is difficult to determine at the point of
use. Other interventions that may be effective aids in
assessing overdose risk include point-of-use testing, also
known as drug checking, and qualitative user discern-
ment of street heroin. Recent research has shown a high
willingness among younger, US-based injection drug
users to utilize fentanyl test strips [83], but the hyper-
sensitivity of on-the-market fentanyl test strips raises
questions about their efficacy in helping injectors to
quantify risk. Harm reduction interventions focusing on
“universal precautions,” i.e., consistent use of drug
sampling, may be more effective than point-of-use fen-
tanyl testing. This and the utility of combined interven-
tions need to be evaluated. User discernment of
fentanyl-adulterated and -substituted heroin may also be
a useful supplement to both drug sampling and point of
use testing [40].
This study is explorative qualitative research based on
a convenience sample of heroin injectors in five US
states. Due to the non-random sampling methods and
semi-structured interview format, quantitative compari-
sons of drug sampling patterns across the research loca-
tions or by sample characteristics should not be made.
The data comprise a snapshot of drug consumption be-
havior that can generate hypotheses but not conclusive
findings. Interviews carried out at needle and syringe
programs and other public health settings may be influ-
enced by social desirability bias. Some interviewees were
recruited outside of these environments, however, in an
effort to mitigate this bias.
Conclusions
Harm reduction services are central in the promotion of
safer drug use techniques. Bearing in mind the non-
random study sample, we found heroin sampling methods
to be most common in Baltimore and Chicago, where ro-
bust harm reduction services have been established for
more than two decades (Baltimore’s in 1994 and Chicago’s
in 1991). In Massachusetts, two of the three cities visited
had no official needle and syringe programs, while
Worcester’s had only started in 2016, and few users men-
tioned using tester shots or other drug sampling methods.
In Chicago, where most of those using tester shots and
snorting were interviewed, the local harm reduction ser-
vice, Chicago Recovery Alliance [84], has been teaching
these methods for two decades. Snorting, for those willing
to do so, was considered a particularly informative method
for evaluating the drug as it included other sensations,
allowing users to detect pH balance, additives, and other
drug characteristics.
The use of tester shots and other drug sampling
methods as a means of preventing an overdose from injec-
tion drug use reduces the quantity absorbed at any one
time, allowing users to monitor for drug strength and
titrate their dose accordingly. In the face of greater per-
ceived susceptibility to and severity of opioid-related over-
dose due to the rising presence of fentanyl-adulterated
and -substituted heroin [40], this could be a useful strat-
egy to reduce both morbidity and mortality.
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